1   **Title page**

2

3   **Can rapeseed oil replace olive oil as part of a Mediterranean-style diet?**

4

5   Richard Hoffman & Mariette Gerber[1]

6

7   Richard Hoffman (corresponding author)

8   School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10
9   9AB, UK

10   Tel. +44 1707 284526

11   Fax: +44 1707 285046

12   E-mail: r.hoffman@herts.ac.uk

13

14   [1] Mariette Gerber

15   Expert at French Food, Environment and Work Safety Agency (ANSES), Former
16   INSERM Senior Scientist, Cancer Institute, 34298, Montpellier, cedex 5, France

17   E-Mail: mariette.gerber@sfr.fr

18

19   *Running title*

20   Rapeseed versus olive oil

21

22   *Keywords*

23   Rapeseed oil; Canola oil; Olive oil; Mediterranean diet

24

25

Abstract

This narrative review compares evidence from experimental, epidemiological and clinical studies of the health benefits of rapeseed (Canola) oil and olive oil in order to assess if rapeseed oil is suitable as a sustainable alternative to olive oil as part of a Mediterranean-style diet in countries where olive trees do not grow. From epidemiological studies, the evidence for cardiovascular protection by extra virgin olive oil is "convincing", and for cancers "limited-suggestive", especially oestrogen receptor negative breast cancer, but more studies are required in relation to cognitive impairment. Evidence for rapeseed oil is limited to short term studies on biomarker risk factors for cardiovascular disease. Any benefits of rapeseed oil are likely to be due to α-linolenic acid, but this is prone to oxidation during frying. We conclude that due to a lack of evidence from observational or intervention studies indicating that rapeseed oil has comparable health benefits to extra virgin olive oil, rapeseed oil cannot currently be recommended as a suitable substitute for extra virgin olive oil as part of a Mediterranean-style diet.

Abbreviations

MD	Mediterranean diet
EVOO	extra virgin olive oil
OO	either virgin or non-virgin olive oil (not specified)
RO	rapeseed (Canola) oil
ALA	α-linolenic acid
TFA	*trans* fatty acid
UFA	unsaturated fatty acid

Introduction

The traditional Mediterranean diet (MD) is widely recognised as one of the healthiest in the world, and it is likely that more widespread adoption of this diet in non-Mediterranean countries would lead to a significant reduction in the incidence of many chronic diseases[1]. Some health organisations in non-Mediterranean countries now recommend a MD. For example, in the UK a MD is recommended by NICE (National

Institute for Health and Care Excellence) for secondary prevention following a myocardial infarction[2]. However, despite this type of targeted advice, there is only limited promotion of a MD to the general population in non-Mediterranean countries[3], and campaigns for healthy eating tend to focus on promoting diets that are compatible with the cultural heritage of a people. For example, Public Health England promotes the Eatwell Plate - a dietary pattern modelled on a healthy UK-based diet[4], and in Norway the traditional Norwegian diet has been promoted as being more appropriate for this country than adopting a MD[5].

Nevertheless, it can be argued that the well-proven health benefits of the MD justify it being more widely promoted in non-Mediterranean countries. Promoting a MD in non-Mediterranean countries is a viable public health approach since there is usually good compliance to this diet by individuals in non-Mediterranean countries who adopt it, and, in general, eating habits in many countries are becoming more flexible[6, 7]. In addition, local produce can be used, rather than foods that only grow in Mediterranean countries, since food choices for a MD are mostly based on food groups, such as "fruits" or "vegetables", rather than on specific foods[8]. Indeed, it has been argued that many features of recommended dietary patterns in Northern Europe, such as high consumption of fruit and vegetables and low consumption of meat, are quite similar to the MD[9].

One exception to the generalised recommendation of food groups, rather than specific foods, is to consume olive oil (OO) as the main source of added fat. Indeed, it is the consumption of OO - more than any other single factor - that distinguishes the traditional MD from other dietary patterns[10]. However, adopting OO as the main dietary fat as part of a MD in non-Mediterranean populations may present an obstacle since it is relatively costly compared with other cooking oils, and consumption of OO in non-Mediterranean populations is low[11]. Consuming large quantities of OO in non-Mediterranean countries also raises issues of food security. The food security agenda aims to increase production of foods within national borders in order to guarantee food production independent of international influences. Since olive trees only grow in Mediterranean type climates this may not be compatible with food security issues, although this is less of an issue between EU countries which share interdependent policies.

91

The health benefits of OO are attributed both to its high content of the MUFA oleic acid[12] and to various minor components[13]. Rapeseed oil (RO) (known as Canola oil in the US, Canada and some other countries) is a potential substitute for OO since it has a similar MUFA content to OO and its overall fatty acid profile is favourable due to a low content of SFA and high content of PUFA, including α-linolenic acid (ALA). Consumption of RO is now high in many non-Mediterranean countries, partly due to low cost, and also because it is perceived as being a healthy oil. There is increasing substitution of RO for OO, such as in recipes for the home cook, and in the UK NICE do not specify OO in their description of a MD but instead refer to "vegetable oil" - which in the UK generally refers to RO[2]. Hence, perhaps not surprisingly, consumption of RO in the UK may now be starting to displace that of OO since OO sales have seen their first fall in over 20 years[14].

104

Rapeseeds are widely grown - both for biofuel and for human consumption - in many EU countries, Canada, China, Australia and India[15]. In the UK, rapeseeds are the only oilseeds harvested in significant quantities. In view of the relatively low cost and the ready availability of RO, we examine if the health benefits of RO justify it replacing OO as part of wider recommendations for consumption of a MD in non-Mediterranean countries, and so ask if RO can be regarded as an ersatz "Northern OO" for the domestic consumer.

112

Methods

We used a narrative review approach, and searched electronic databases PubMed and Scopus up until April 2014. Key words "olive oil", "virgin olive oil", "rapeseed oil" and "Canola" were used in combination with keywords "composition" (and related words such as "phenolics", "antioxidants"), "cardiovascular disease" (and related words such as "coronary heart disease" and "myocardial infarction"), "cancer" and "neurodegenerative disease" (and related words such as "Alzheimer's disease" and "dementia") and the study method (such as "cohort" and "meta analysis").

121

122   **Composition**

123   *Fats*

124   As well as a high MUFA content (mainly oleic acid), OO also contains a range of other

125   FAs[16]. Levels of the various FAs in OO vary quite widely between oils depending on

126   factors such as the type of olive tree cultivar used for oil production (see Table 1). RO

127   also has a high MUFA content, as well as considerably higher levels of ALA than OO

128   (see Table 1). Consumption of ALA is linked to cardioprotective benefits (see below).

129   However, RO also contains approx. 1% *trans* isomers of ALA, which are produced

130   during the deodorisation step of oil production[17, 18]. There is a well-established link

131   between *trans* fatty acid (TFA) consumption and increased risk of CHD[19] and

132   although the level in RO does not in itself constitute a health risk, it is desirable to keep

133   levels of TFA to a minimum.

134

135   RO is very low in SFAs, comprising only approx. 6% of total FAs. This is about half

136   the average content of SFA in OO, and it has been argued that this gives RO an

137   advantage over OO[20]. However, the quite low proportion of SFA even in OO means

138   that it would not normally be a significant daily source of SFA compared to other

139   dietary sources such as meat or dairy produce. For example, 20 ml OO contains 128

140   mg SFA giving 9.62 kJ (2.3 kcal) as SFA. Current UK intake of SFA is 12.7 % of total

141   energy intake[21]. Hence, consumption of 20 ml OO represents less than 1% of the

142   average daily intake of energy in the UK from SFA (0.9% total calories in women

143   based on an intake of 8368 kJ (2000 kcal) and 0.7% in men based on an intake of

144   10460 kJ (2500 kcal)).

145

146   *Minor components*

147   There are significant differences between the minor components in RO and extra virgin

148   olive oil (EVOO), due not only to the source of the oil but also to production methods.

149   EVOO is produced using mild conditions that include pressing olive fruits at low

150   temperature, washing with water, filtration and centrifugation. These conditions retain

151   many of the original components of the olives. The most abundant minor component is

152   the hydrocarbon squalene, and there are smaller quantities of carotenoids, triterpenoids,

153   phytosterols (eg β-sitosterol, Δ^5-avenasterol and campesterol) and tocopherols (approx.

154 95% α-tocopherol) (Table 1). EVOO also contains a wide variety of phenolic
155 compounds including secoiridoids (eg oleuropein) and their phenolic derivatives (eg
156 tyrosol, hydroxytyrosol), flavonoids (eg luteolin, apigenin), and lignans (pinoresinol
157 and acetoxypinoresinol). EVOO is the best quality OO and must meet predefined
158 criteria in terms of sensory qualities and limits of acidity. Other OOs have substantially
159 lower levels of most of the minor components, and phenolic compounds in particular
160 are reduced[16].

161

162 Many potentially beneficial biological actions have been described for the minor
163 components in EVOO. EVOO phenolics reduce markers for inflammation and
164 oxidative stress *in vitro* and *in vivo*[22, 23]. Squalene reduces oxidative stress in human
165 mammary epithelial cells[24]. Lignans are phytoestrogens with possible anticancer
166 activity[25], and it is noteworthy that OO (both EVOO and other OO) was found to be
167 the major dietary source of lignans in participants in the PREDIMED study[26].
168 Secoiridoids such as oleuropein and its derivatives are of particular interest in relation
169 to the health properties of EVOO since they are not found in other food plants.

170

171 Standard production of RO requires a far higher level of processing including solvent
172 extraction of the oil from the pressed seeds, and refining by degumming,
173 neutralization, bleaching and deodorization. As a consequence, most of the minor
174 constituents that were originally present in the rapeseeds are significantly depleted in
175 the oil. Some of the phytosterols (which include β-sitosterol, campesterol and
176 brassicasterol) and tocopherols (mainly α- and γ-tocopherol, in a ratio of approx. 1:2)
177 are lost, as are most or all of the phenolics originally present (which includes a high
178 proportion of sinapic acid and its derivatives)[27]. Phytosterols are best know for their
179 ability to reduce cholesterol uptake from the gut, although some, such as Δ^5-
180 avenasterol, possess antioxidant activity.

181

182 **Cooking**
183 Consumption of raw EVOO is often quite high in Mediterranean cuisine, and this may
184 be important since compositional changes can occur to oils during cooking (see
185 below). Raw EVOO is used as a salad dressing or simply poured on bread, as a main
186 ingredient in many dips and sauces and as an addition to stews at the end of cooking to

187   enhance flavour. Whereas some people prize EVOO for its flavour, it is unclear if the

188   flavour of raw RO would be an acceptable substitute. OO is also consumed after frying

189   and baking due to oil being absorbed into the cooked food. Large quantities of OO are

190   consumed in the *lathera* dishes of some eastern Mediterranean countries since the

191   cooking oil in which vegetables are cooked is consumed as an integral part of the dish.

192   OO is more commonly used for shallow frying (which typically requires an oil

193   temperature of 140-160°C) rather than deep-frying (180-190°C) due to its relatively

194   low smoke point.

195

196   There can be significant thermal degradation of fatty acids and minor components in

197   oils during cooking, and this may potentially have detrimental health effects.

198   Undesirable changes include the hydrolysis and polymerisation of triglycerides,

199   oxidation of fatty acids and sterols, and generation of TFAs. Lipid oxidation is

200   influenced by various factors such as the type of food present, the proportion of oil

201   exposed to the air, and the amount of unsaturated fats (UFA) in the oil. Oxidation

202   increases with the degree of unsaturation: ALA (18 : 3n-3) is 2.4 times more reactive

203   than linoleic acid (18 : 2n-6) which is 40 times more reactive than oleic acid (18 : 1n-

204   9)[28]. This is of potential concern for RO due to its high ALA content. Prolonged and

205   repeated deep frying with RO, as may occur in commercial establishments, can also

206   lead to the generation of quite high levels of TFAs[29].

207

208   ***Loss of antioxidants***

209   During frying, antioxidants in oils are lost due both to direct thermal degradation and

210   by acting as antioxidants and so being consumed during the thermal oxidation of

211   unsaturated fats[30]. EVOO contains a favourable ratio of antioxidants to PUFAs

212   compared to other types of oils, and this reduces both the rate at which antioxidants are

213   lost and the rate of lipid oxidation that occurs during frying[31, 32]. Antioxidants in

214   EVOO deplete at different rates, as demonstrated in a study by Gomez-Alonso et al

215   who found that hydroxytyrosol was depleted to a far greater extent than tyrosol when

216   EVOO was used for frying potatoes at 180°C for 10 min[33]. Phenolics in EVOO help

217   stabilise vitamin E during heating and vitamin E in turn helps protect PUFAs from

218   oxidative degradation[31].

219

220   Despite losses of minor components due to frying, heated virgin OO (VOO) has been
221   shown to retain beneficial effects on postprandial inflammation. VOO repeatedly
222   heated to 180°C suppressed postprandial inflammation in obese subjects (determined
223   as NFκB activation in peripheral blood monocytes) compared to a seed oil with similar
224   fat content (a blend of high oleic acid sunflower oil and RO)[34]. Although the heating
225   protocol completely depleted hydroxytyrosol in the VOO, other minor components,
226   including some phenolics, were retained.

227

228   In summary, although antioxidants in EVOO are reduced during frying, using EVOO
229   rather than other types of OO for frying may be justified as a means to minimise
230   oxidation of the relatively low content of PUFAs and to reduce postprandial
231   inflammation. Antioxidants in EVOO have also been to shown to migrate into the food
232   during cooking and so may confer health benefits in the body[35, 36].

233

234   Antioxidants in RO include phytosterols, vitamin E and Coenzyme Q, although levels
235   of phenolics are very low compared to EVOO (see Table 1). Vitamin E content was
236   reduced by two-thirds when RO was heated at 150°C for 6 h[30], and vitamin E was
237   also significantly depleted using conditions designed to replicate RO being used for
238   deep frying[37]. The concentration of ALA in RO is a major determinant of the extent
239   of fatty acid oxidation[38]. The relatively low ratio of antioxidants to PUFAs in RO
240   may lead to significant losses of antioxidants and increase lipid peroxidation, although
241   this will depend on the time period and temperature used for frying. The more
242   favourable balance between antioxidants and PUFAs in EVOO may retain more
243   antioxidants.

244

245   *Generation of toxic compounds*
246   Insufficient protection of PUFAs from oxidation leads to their conversion to
247   hydroperoxides and these may break down to various volatile compounds[39]. Some,
248   like acetaldehyde and acrolein (2-propenal), are toxic. Acetaldehyde is classified as a
249   carcinogen by the EU, whereas the main health effect of exposure to acrolein is
250   irritation of the eyes, the mucosae and the skin[40]. It is therefore desirable to minimise
251   exposure of the cook to toxic volatile compounds produced during frying. Fullana et al
252   reported that acetaldehyde production at 180°C was twice as high for RO compared

8

253   with either OO or VOO[41], although levels from all oils were low, and no acetaldehyde

254   emissions were detected by Katragadda et al at 180°C[42]. Production of acrolein by RO

255   at 180°C was found to be approximately five times higher than acrolein production by

256   either EVOO or OO[41, 42]. This is probably due to the high ALA content of RO since

257   recent studies indicate that thermal degradation of ALA is the main source of acrolein

258   in RO[43, 44]. The presence of antioxidants in EVOO such as chlorophylls, pheophytins

259   and carotenoids, may also reduce acrolein formation compared with RO[45]. Despite the

260   generation of some toxic volatiles, especially by RO, there is no evidence that, under

261   normal domestic conditions, using fresh RO for shallow frying is likely to pose a

262   health risk through inhalation.

263

264   In summary, there exists a clear advantage for EVOO over RO in terms of the former's

265   richer composition, limited processing without solvent extraction and deodorization,

266   and safety of use in cooking.

267

268   **Health**

269   Various studies have assessed the health benefits of OO and RO. Several expert

270   committees have described the basis for making a robust judgement of a causal

271   relationship between a nutrient or food and disease risk[46, 47]. Consistency between

272   several observational studies is necessary, with prospective studies favoured over case-

273   control studies. When available, there should be randomized controlled trials (RCT) of

274   sufficient size and duration, with more weight being given to disease incidence as an

275   endpoint rather than to biological markers. Experimental studies, both *in vivo* and *in*

276   *vitro,* can provide biological plausibility. We follow these guidelines for assessing the

277   respective health benefits of OO and RO. Epidemiological studies are summarised in

278   Tables 2 and 3.

279

280   ***OO and health***

281   *Cardiovascular diseases*

282   Many epidemiological studies, including RCT, have shown that a Mediterranean

283   dietary pattern that includes OO is convincingly associated with a reduced risk of

284   CVD, and is probably associated with a reduced risk of certain cancers and

285 neurodegenerative diseases (reviewed in[48]). Only a few of these epidemiological

286 studies have focused on the specific effect of OO. Ancel Keys, the pioneer advocate of

287 the MD, first proposed that it was the ratio of MUFA:SFA that was the key component

288 for the health benefits of the MD[49]. Although this suggested that the importance of

289 OO was to provide MUFA, later on it was established that MUFA from sources other

290 than OO (animal fat contains 40 to 45 % of MUFA) did not have the same beneficial

291 effect[50].

292

293 Consequently, studies were undertaken to decipher the specific effect of OO. In the

294 Three-City Study, those with intensive use of OO showed a lower risk of stroke

295 compared to those who never used OO[51]. In the Italian-EPIC cohort, women with a

296 high OO consumption had reduced incidence risk of non-fatal and fatal myocardial

297 infarction[52], although it should be noted that this study has been criticised because it

298 was not fully adjusted. In another analysis conducted on the EPIC population in Spain,

299 a high intake of OO decreased the risk of overall mortality by 26% and of CVD deaths

300 by 44%[53]. A recent meta analysis by Martinez-Gonzalez et al comparing high versus

301 low intake of OO found a significant risk reduction for stroke, but the risk reduction

302 for CHD was not significant (Table 2)[54].

303

304 In the studies included in the meta analysis by Martinez-Gonzalez et al, only that by

305 Buckland et al distinguished between OO and EVOO. In this well-conducted study

306 from Spain, there was a reduction of CVD incidence of 7% for each 10g increase of

307 OO per 8.4 MJ ingested, and this effect was greater for EVOO (risk reduction 14%)[55].

308 The role of EVOO was examined in the PREDIMED randomised control trial.

309 Participants at high vascular risk were randomly allocated to three groups. Two groups

310 received a typical MD supplemented with either EVOO (1 litre/week) or mixed nuts

311 (30 g/day). The third, control group was advised to follow a low-fat diet. In the two

312 groups that received advice on the MD, the risk of CVD (myocardial infarction, stroke

313 or death from cardiovascular disease) was reduced by approximately 30%[56]. Recent

314 additional analysis of the PREDIMED study provides further evidence for a superior

315 benefit for EVOO versus non-virgin OO in CVD risk. This observational prospective

316 cohort analysis was based on baseline consumption of OO ie prior to randomisation

317 into groups. In individuals at high cardiovascular risk, there was a statistically

318 significant reduction in total cardiovascular risk and stroke (but not myocardial

319   infarction) for total OO consumption or for consumption of EVOO, but not for

320   consumption of non-virgin OO[57] (see Table 2). These results remained even after

321   adjusting for adherence to a MD. The results highlight the possible important

322   contribution of minor components in EVOO for cardiovascular protection.

323

324   Short-term studies with cardiovascular risk factors as end-points also suggest that

325   phenolics are important for the cardiovascular benefits of VOO. For example, the

326   EUROLIVE study, comparing OO high and low in phenolics, found a linear increase

327   in HDL cholesterol levels for low-, medium-, and high-polyphenol olive oils, and a

328   linear decrease in oxidized LDL levels[58]. A reduction in LDL oxidation for EVOO

329   with a minimum hydroxytyrosol content is the basis for a recent health claim issued by

330   the European Food Safety Authority for the health benefits of OO[59]. VOO, as part of a

331   Med diet, has also been shown to reduce levels of circulating inflammatory molecules

332   associated with increased cardiovascular risk[60].

333

334   Experimental models *in vitro* and *in vivo* suggest that VOO can favourably alter many

335   stages in atherosclerosis. VOO was shown to reduce atherosclerosis in apo-E deficient

336   mice and hamsters[61]. Anti-inflammatory activities of minor components in VOO

337   include reducing prostacyclin synthesis in human vascular smooth muscle cells,

338   inhibiting cyclo-oxygenases[62], and inhibiting endothelial adhesion molecule

339   expression[63]. Phenolics also have favourable effects on haemostasis[64]

340

341   Although many studies indicate that cardiovascular risk is reduced when MUFA

342   replaces dietary SFA or carbohydrates[65], epidemiological evidence for a specific role

343   for the oleic acid in OO for cardiovascular protection is limited. However, short term

344   feeding studies in humans suggest that one benefit of diets rich in OO is that they do

345   not have the adverse effects on post-prandial inflammation and haemostasis seen with

346   diets rich in SFA[12]. OO also has beneficial hypotensive effects in short term feeding

347   studies[12], and oleic acid is implicated in these effects since, in rat models, triolein (the

348   main TAG in OO, consisting of 3 oleic acid moieties) reduced blood pressure as

349   effectively as VOO[66].

350

351   *Cancers*

352 A beneficial effect of adherence to a MD (as assessed by a Mediterranean diet score)
353 and reduced cancer risk is found to be greater in Mediterranean, rather than non-
354 Mediterranean, populations[8]. The overall cancer mortality in the Spanish study quoted
355 above showed a RR <1 but was non significant[53]. In the PREDIMED study, no
356 statistically significant associations were found for consumption of any type of OO and
357 mortality from all types of cancer[54]. However, different cancer sites are characterized
358 by different risk factors and for some types of cancer there are indications of a specific
359 effect of OO, and this is supported by several *in vitro* and *in vivo* experimental
360 studies[67]. A meta-analysis of 25 studies reported risk reduction for upper digestive
361 and respiratory tract cancers, breast and, possibly, colorectal and other cancer sites[68].
362 Similarly, *a posteriori* dietary pattern analysis has demonstrated a greater risk
363 reduction in breast cancer when OO was present in the pattern[69-71]. A more recent
364 study addressed the question of OO and breast cancer in the Mediterranean countries of
365 the EPIC study and observed a non-significant risk reduction for oestrogen receptor
366 negative (ER-) progesterone receptor negative (PR-) breast cancers with a high OO
367 intake[72]. These cancers are independent from hormonal factors and differ from ER+
368 breast cancers in terms of risk factors. However, they represent only 25 to 30% of all
369 breast cancers and the lack of statistical power might explain the large CI seen in this
370 study (see Table 2). This epidemiological observation is supported by an experimental
371 model showing that the OO phytochemical oleuropein is more cytotoxic for basal-like
372 ER- MDA-MB-231 cells than for luminal ER+ MCF-7 cells[73].

373

374 *Neuro-degenerative diseases*
375 In the prospective Three City Study, OO was associated with a decrease in cognitive
376 impairment[74]. In participants of the PREDIMED study, consumption of some foods
377 was independently associated with better cognitive function. Among them, total OO
378 positively correlated with immediate verbal memory and EVOO with delayed verbal
379 memory[75]. More recently, in the PREDIMED-Navarra trial, 285 participants at high
380 vascular risk were randomly allocated to three groups: a MD supplemented with
381 EVOO, a MD supplemented with mixed nuts, a low-fat diet. Lower mild cognitive
382 impairment was observed in the EVOO group compared to the control group[76].
383 Participants assigned to the MD + nuts group did not differ from controls. Various anti-
384 oxidant and anti-inflammatory phenolics in EVOO may contribute to these beneficial
385 effects since oxidative stress and inflammation are associated with neuro-

386 degeneration[77]. More specific effects have also been described for EVOO phenolics.

387 Tyrosol and hydroxytyrosol have been shown to decrease activation by β amyloid (Aβ)

388 of the pro-inflammatory transcription factor NFκB in cultured neuroblastoma cells[78].

389 In mouse models of Alzheimer's disease where there is increased Aβ, the EVOO

390 phenolics oleocanthal and oleuropein reduced Aβ levels and plaque deposits[79, 80] and

391 improved memory[81].

392

393 The severity of skin photo-aging was significantly attenuated by the consumption of

394 MUFA from OO in subjects of the SUVIMAX cohort[82]. Only MUFA from OO was

395 efficient, suggesting that phenolics or squalene in OO might be responsible for the

396 beneficial effect on skin photo-aging.

397

398 In summary, based on recognised criteria of evidence in human studies, the level of

399 evidence for the relationship of EVOO with CVD can be qualified as "convincing",

400 and for cancers as "limited-suggestive", especially ER- breast cancer. For aging and

401 cognitive impairment, fewer data exist in favour of a specific beneficial effect of OO,

402 and require confirmation. There is good evidence from both human and experimental

403 studies that phenolics present in EVOO are important for the cardiovascular benefits.

404 More limited experimental studies also suggest that phenolics are important for the

405 anti-cancer and neuro-protective effects of EVOO.

406

407 ***RO and health***

408 Whereas many studies have examined the relationship of OO with disease incidence or

409 mortality as well as biomarkers for disease, studies with RO are mainly limited to

410 outcomes based on biomarkers. Two recent reviews received funding from the food

411 industry and the RO industry[83, 84], hence leading to possible conflicts of interest[85, 86].

412 Most studies with RO have used raw RO. This limits the interpretation of these studies

413 since most RO is consumed after frying and this can cause significant changes in

414 composition, especially of ALA, as discussed above.

415

Cardiovascular disease

A number of reports comparing RO with a source of SFA on biomarkers of CVD risk (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, lipid peroxidation and inflammatory biomarkers) have found that RO is relatively beneficial, as it is an oil low in SFA and high in MUFA+PUFA[84]. As the U.S. Food and Drug Administration put it in the qualified health claim for canola (rapeseed) oil in 2006: "Limited and not conclusive scientific evidence suggests that eating about 1.5 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day."[87]

It is the generally accepted view that the benefits to heart health are greater when SFA is replaced with PUFA, rather than when SFA is substituted with MUFA[50]. Since there are no observational studies with RO, a review of epidemiological studies of the specific effect of ALA is relevant, albeit with the proviso of possible changes due to frying. These are summarised in Table 3. A review by the Afssa expert group in 2008 concluded that results on mortality were inconsistent[88]. Whereas Folsom et al 2004 observed a modest risk reduction of total mortality in the IOWA women study[89], two studies from the Nurse's Health Study cohort found an effect on mortality only from a sudden cardiac event[90, 91]. Similarly, two studies from the Health Professional Study showed a risk reduction of myocardial infarction[92, 93]. An interesting finding was the observation that there was a risk reduction by ALA when the EPA + DHA consumption was < 100 mg/day, and that this effect was lost when EPA + DHA consumption was ≥ 100 mg/day with a significant interaction ($p = 0.003$ for myocardial infarction and $p = 0.006$ for total CVD) between the two intakes. Similarly, the risk reduction observed for fatal IHD in a prospective study based on measurement of ALA in phospholipids was abolished after adjusting for EPA+DHA[94]. Two prospective studies based on ALA intake and conducted in Northern Europe, the ATBC study[95] and the Zutphen study[96] did not show any significant association.

More recently, another study based on circulating and dietary ALA found no effect of this fatty acid on congestive heart failure[97]. In a meta-analysis published in 2012,

449 there was a borderline significant risk reduction for CVD, and only fatal CHD was

450 significant [98]. A large unexplained heterogeneity was present in this meta-analysis,

451 casting doubts on the results. A more recent analysis using a pooled study design found

452 a non-significant inverse association between ALA intake and CHD risk in men, but no

453 consistent association in women[99]. There has also been a report of a moderate non-

454 linear association of ALA with heart failure[100], and one showing no association of

455 ALA with atrial fibrillation[101].

456

457 Several studies have compared RO with OO on risk factors for CVD. A hypoenergetic

458 RO-containing diet (supplied as oil and margarine) reduced systolic blood pressure,

459 and total and LDL cholesterol to a comparable extent as a refined OO diet, and also

460 resulted in a greater reduction in diastolic blood pressure, probably because of the

461 higher ALA content of the RO diet[102]. In another study, RO resulted in a reduction of

462 total cholesterol of 12% versus 5.4% for OO, but HDL was also significantly reduced

463 in the RO group, but not with OO[103]. In a further study, 18 subjects in 6 experimental

464 cross-over groups received 50g of oil / 10 MJ in a diet of 15 MJ. After three weeks,

465 there was a significant reduction of LDL cholesterol in the RO group which is

466 expected since RO contains 21% PUFAs[104]. All other biomarkers were not

467 significantly different. With the same study design, the same group later published

468 results on TAG. After three weeks, fasting TAG were significantly higher for the OO

469 regimen, with no difference on either post-prandial TAG nor on susceptibility to

470 lipoprotein oxidation[105].

471

472 In conclusion, despite limited evidence of benefits of RO in short term studies on

473 biomarker risk factors for CVD, there are currently no observational and intervention

474 studies to suggest that RO has the cardiovascular benefits of EVOO. Any benefits of

475 RO are likely to be due to ALA.

476

477 *Cancer*

478 ALA has been associated with an increased risk of prostate cancer, but results are

479 inconsistent. A meta-analysis did not find an association between dietary ALA intake

480 and prostate cancer risk[106], although a more recent study has found that ALA

481 increased the risk of advanced prostate cancer in elderly men[107] (Table 3). There are

482   indications of risk for gastric cancer[108]. Inhalation of the vapours from unrefined RO

483   with a high content of ALA used for cooking was associated to cancers in China[109].

484

485   We did not conduct searches for the effects of RO on other diseases.

486

487   **Recent developments**

488   The increased susceptibility of ALA to oxidation has led to the commercial

489   development of modified ROs with decreased ALA. These include a low linolenic acid

490   canola oil (LLCO), which has an increased linoleic acid content, and a high oleic

491   canola oil (HOCO)[15]. These modified oils have better heat stability[37], but they are

492   more expensive than standard RO. There are currently no clinical studies on their

493   effects on health. However, as noted above, reducing ALA and increasing MUFA may

494   reduce possible cardioprotective benefits of RO.

495

496   A second approach has been to increase the level of antioxidant phytochemicals in RO.

497   In 2006 the EU funded project "Optim'Oils" was initiated with the aim of improving

498   production methods for RO. An oil with significantly lower 18:3 *trans* and improved

499   phytochemical composition (minimised losses of phytosterols, tocopherols and

500   phenolics) was successfully developed[17]. In a clinical study, total-/HDL-cholesterol

501   and LDL-/HDL-cholesterol were increased by 4% (p<0.05) with consumption of raw

502   standard RO and there were also non-significant increases in ox-LDL. These increases

503   were not seen with the optimised oil[110], and hence there were modest benefits of the

504   optimised RO compared to the standard RO.

505

506   Another interesting way forward is to incorporate olive phenolics into RO. The waste

507   water from OO production (olive mill waste water, OMWW) contains high levels of

508   some olive phenolics[111], and disposal of OMWW is of major environmental

509   concern[112]. An OMWW extract has been used to improve the oxidative stabilities of

510   lard[113], sunflower oil[114] and refined OO[115]. A seed oil comprising 30% high-oleic

511   sunflower oil and 70% RO enriched with OMWW was found to reduce postprandial

512   inflammation in obese subjects as effectively as VOO, even after 20 cycles of heating

513   the oils at 180°C[34]. Incorporation of phenolics from OMWW also has the potential to

514 improve the cardiovascular health benefits of RO since OMWW, which has high levels
515 of hydroxytyrosol, has been shown to reduce LDL oxidation[116].
516

517 **Conclusions**

518 The extensive evidence for health benefits of EVOO is not matched by similar data for
519 RO, and based on current evidence, RO cannot be recommended as equivalent in terms
520 of health benefits compared to EVOO. There are significant losses of minor
521 constituents during the processing of standard RO and there may also be deleterious
522 changes in FA composition when RO is used for cooking. New initiatives to alter the
523 production methods and composition of RO are addressing some of these issues and
524 could lead to a far healthier, albeit more expensive, product for the consumer in the
525 future. Nevertheless, RO lacks many of the constituents in EVOO, such as secoiridoids
526 and derivatives, which are thought to be important for its health benefits and desirable
527 stability during cooking. The use of OMWW to stabilise RO and improve its health
528 benefits may be of mutual benefit to both industries by using an environmentally
529 polluting waste product from the OO industry to the benefit of producing a healthier
530 product for the RO industry. However, the current high fungicide usage on the oilseed
531 rape crop is also of concern[117].
532

542 **References**
543

17

544 1. Sofi F, Abbate R, Gensini GF *et al.* (2011) Accruing evidence on benefits of

545 adherence to the Mediterranean diet on health: an updated systematic review and meta-

546 analysis. *Am J Clin Nutr* **92**, 1189-1196.

547 2. NICE (2013) Myocardial infarction: secondary prevention (CG172).

548 3. Piscopo S. (2009) The Mediterranean diet as a nutrition education, health promotion

549 and disease prevention tool. *Public Health Nutr* **12**, 1648-1655.

550 4.   NHS   Choices   The   eatwell   plate.

551 http://www.nhs.uk/Livewell/Goodfood/Pages/eatwell-plate.aspx (accessed 5 February,

552 2014)

553 5. Bere E & Brug J. (2009) Towards health-promoting and environmentally friendly

554 regional diets - a Nordic example. *Public Health Nutr* **12**, 91-96.

555 6. Logan KJ, Woodside JV, Young IS *et al.* (2010) Adoption and maintenance of a

556 Mediterranean diet in patients with coronary heart disease from a Northern European

557 population: a pilot randomised trial of different methods of delivering Mediterranean

558 diet advice. *J Hum Nutr Diet* **23**, 30-37.

559 7. Papadaki A & Scott JA. (2008) Follow-up of a web-based tailored intervention

560 promoting the Mediterranean diet in Scotland. *Patient Education and Counseling* **73**,

561 256-263.

562 8. Hoffman R & Gerber M. (2013) Evaluating and adapting the Mediterranean diet for

563 non-Mediterranean populations: a critical appraisal. *Nutr Rev* **71**, 573-584.

564 9. Bere E & Brug J. (2010) Is the term 'Mediterranean diet' a misnomer? *Public Health*

565 *Nutr* **13**, 2127-2129.

566 10. Lopez-Miranda J, Perez-Jimenez F, Ros E *et al.* (2010) Olive oil and health:

567 summary of the II international conference on olive oil and health consensus report,

568 Jaen and Cordoba (Spain) 2008. *Nutr Metab Cardiovasc Dis* **20**, 284-294.

569 11. Linseisen J, Welch AA, Ocke M *et al.* (2009) Dietary fat intake in the European

570 Prospective Investigation into Cancer and Nutrition: results from the 24-h dietary

571 recalls. *Eur J Clin Nutr* **63 Suppl 4**, S61-80.

572 12. Bermudez B, Lopez S, Ortega A *et al.* (2011) Oleic acid in olive oil: from a

573 metabolic framework toward a clinical perspective. *Curr Pharm Des* **17**, 831-843.

574 13. Cicerale S, Conlan XA, Sinclair AJ *et al.* (2009) Chemistry and health of olive oil

575 phenolics. *Crit Rev Food Sci Nutr* **49**, 218-236.

576 14. MailOnline (2013) Rapeseed oil sales soar as middle class cooks turn to it instead
577 of olive oil because it has half the amount of saturated fat.
578 http://www.dailymail.co.uk/news/article-2335289/ (accessed 5 February, 2014)

579 15. Przybylski R (2011) Canola/Rapeseed Oil. In *Vegetable oils in food technology :*
580 *composition, properties and uses*, 2nd ed. ed., pp. 107-136 [FD Gunstone, editor].
581 Oxford: Wiley-Blackwell.

582 16. Boskou D (2011) Olive Oil. In *Vegetable oils in food technology : composition,*
583 *properties and uses*, 2nd ed. ed., pp. 243-271 [FD Gunstone, editor]. Oxford: Wiley-
584 Blackwell.

585 17. Gladine C, Meunier N, Blot A *et al.* (2011) Preservation of micronutrients during
586 rapeseed oil refining: a tool to optimize the health value of edible vegetable oils?
587 Rationale and design of the Optim'Oils randomized clinical trial. *Contemp Clin Trials*
588 **32**, 233-239.

589 18. Vermunt SH, Beaufrere B, Riemersma RA *et al.* (2001) Dietary trans alpha-
590 linolenic acid from deodorised rapeseed oil and plasma lipids and lipoproteins in
591 healthy men: the TransLinE Study. *Br J Nutr* **85**, 387-392.

592 19. Bendsen NT, Christensen R, Bartels EM *et al.* (2011) Consumption of industrial
593 and ruminant trans fatty acids and risk of coronary heart disease: a systematic review
594 and meta-analysis of cohort studies. *Eur J Clin Nutr* **65**, 773-783.

595 20. Rapeseed Oil Benefits A Healthy Choice.
596 http://rapeseedoilbenefits.hgca.com/guide-to-rapeseed-oil/rapeseed-oil-health-
597 benefits.aspx (accessed 5 February, 2014)

598 21. Levy LB. (2013) Dietary strategies, policy and cardiovascular disease risk
599 reduction in England. *Proc Nutr Soc* **72**, 386-389.

600 22. Servili M, Sordini B, Esposto S *et al.* (2014) Biological Activities of Phenolic
601 Compounds of Extra Virgin Olive Oil. *Antioxidants* **3**, 1-23.

602 23. Cicerale S, Lucas L & Keast R. (2010) Biological activities of phenolic compounds
603 present in virgin olive oil. *Int J Mol Sci* **11**, 458-479.

604 24. Warleta F, Campos M, Allouche Y *et al.* (2010) Squalene protects against
605 oxidative DNA damage in MCF10A human mammary epithelial cells but not in MCF7
606 and MDA-MB-231 human breast cancer cells. *Food Chem Toxicol* **48**, 1092-1100.

607 25. Landete JM. (2012) Plant and mammalian lignans: A review of source, intake,
608 metabolism, intestinal bacteria and health. *Food Research International* **46**, 410–424.

609　26. Tresserra-Rimbau A, Medina-Remon A, Perez-Jimenez J *et al.* (2013) Dietary
610　intake and major food sources of polyphenols in a Spanish population at high
611　cardiovascular risk: the PREDIMED study. *Nutr Metab Cardiovasc Dis* **23**, 953-959.

612　27. Zacchi P & Eggers R. (2008) High-temperature Pre-conditioning of Rapeseed: A
613　Polyphenol-enriched Oil and the Effect of Refining. . *Eur J Lipid Sci Technol* **110**,
614　111-119.

615　28. Frankel EN (2005) *Lipid oxidation*. 2nd ed. ed. Bridgwater: Oily Press.

616　29. Roe M, Pinchen H, Church S *et al.* (2013) Trans fatty acids in a range of UK
617　processed foods. *Food Chemistry* **140**, 427–431.

618　30. Roman O, Heyd B, Broyart B *et al.* (2013) Oxidative reactivity of unsaturated fatty
619　acids from sunflower, high oleic sunflower and rapeseed oils subjected to heat
620　treatment, under controlled conditions. *Food Science and Technology* **52**, 49-59.

621　31. Santos CSP, Cruz R, Cunha SC *et al.* (2013) Effect of cooking on olive oil quality
622　attributes. *Food Research International* **54**, 2016-2024.

623　32. Sacchi R, Paduano A, Savarese M *et al.* (2014) Extra virgin olive oil: from
624　composition to "molecular gastronomy". *Cancer Treat Res* **159**, 325-338.

625　33. Gomez-Alonso S, Fregapane G, Salvador MD *et al.* (2003) Changes in phenolic
626　composition and antioxidant activity of virgin olive oil during frying. *J Agric Food*
627　*Chem* **51**, 667-672.

628　34. Perez-Herrera A, Delgado-Lista J, Torres-Sanchez LA *et al.* (2012) The
629　postprandial inflammatory response after ingestion of heated oils in obese persons is
630　reduced by the presence of phenol compounds. *Mol Nutr Food Res* **56**, 510-514.

631　35. Chiou A, Kalogeropoulos N, Boskou G *et al.* (2012) Migration of health promoting
632　microconstituents from frying vegetable oils to French fries. *Food Chemistry* **133**,
633　1255–1263.

634　36. Kalogeropoulos N, Chiou A, Mylona A *et al.* (2007) Recovery and distribution of
635　natural antioxidants (a-tocopherol, polyphenols and terpenic acids) after pan-frying of
636　Mediterranean finfish in virgin olive oil. *Food Chemistry* **100**, 509–517.

637　37. Przybylski R, Gruczynska E & Aladedunye F. (2013) Performance of Regular and
638　Modified Canola and Soybean Oils in Rotational Frying. *J Am Oil Chem Soc* **90**,
639　1271–1280.

640　38. Warner K & Mounts TL. (1993) Frying stability of soybean and canola oils with
641　modified fatty acid composition. *J Am Oil Chem Soc* **70**, 983–988.

642 39. Moya Moreno MCM, Mendoza Olivares D, Amezquita Lopez FJ *et al.* (1999)
643 Analytical evaluation of polyunsaturated fatty acids degradation during thermal
644 oxidation of edible oils by Fourier transform infrared spectroscopy. *Talanta* **50**, 269–
645 275.

646 40. European Commission (2007) Recommendation from the Scientific Committee on
647 Occupational Exposure Limits for acrolein SCOEL/SUM/32.
648 ec.europa.eu/social/BlobServlet?docId=6862&langId=en

649 41. Fullana A, Carbonell-Barrachina AA & Sidhu S. (2004) Comparison of volatile
650 aldehydes present in the cooking fumes of extra virgin olive, olive, and canola oils. *J*
651 *Agric Food Chem* **52**, 5207-5214.

652 42. Katragadda HR, Fullana A, Sidhu S *et al.* (2010) Emissions of volatile aldehydes
653 from heated cooking oils. *Food Chemistry* **120** 59–65.

654 43. Ewert A, Granvogl M & Schieberle P (2012) Comparative Studies on the
655 Generation of Acrolein as Well as of Aroma-Active Compounds during Deep-Frying
656 with Different Edible Vegetable Fats and Oils. In *Recent Advances in the Analysis of*
657 *Food and Flavors*, pp. 129–136.

658 44. Endo Y, Chieko C, Yamanaka T *et al.* (2013) Linolenic acid as the main source of
659 acrolein formed during heating of vegetable oils. *J Am Oil Chem Soc* **90**, 959-964.

660 45. Procida G, Cichelli A, Compagnone D *et al.* (2009) Influence of chemical
661 composition of olive oil on the development of volatile compounds during frying.
662 *European Food Research and Technology* **230**, 217–229.

663 46. WHO (2003) *Diet, nutrition and the prevention of chronic diseases*. *World Health*
664 *Organization Technical Report Series* no. 0512-3054 (Print) 0512-3054 (Linking).

665 47. World Cancer Research Fund / American Institute for Cancer Research (2007)
666 *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global*
667 *Perspective.* Washington DC: AICR.

668 48. Hoffman R & Gerber M (2012) *The Mediterranean diet : health & science*.
669 Oxford: Wiley-Blackwell.

670 49. Keys A, Menotti A, Aravanis C *et al.* (1984) The seven countries study: 2,289
671 deaths in 15 years. *Prev Med* **13**, 141-154.

672 50. Jakobsen MU, O'Reilly EJ, Heitmann BL *et al.* (2009) Major types of dietary fat
673 and risk of coronary heart disease: a pooled analysis of 11 cohort studies. *Am J Clin*
674 *Nutr* **89**, 1425-1432.

675   51. Samieri C, Feart C, Proust-Lima C *et al.* (2011) Olive oil consumption, plasma

676   oleic acid, and stroke incidence: the Three-City Study. *Neurology* **77**, 418-425.

677   52. Bendinelli B, Masala G, Saieva C *et al.* (2011) Fruit, vegetables, and olive oil and

678   risk of coronary heart disease in Italian women: the EPICOR Study. *Am J Clin Nutr* **93**,

679   275-283.

680   53. Buckland G, Mayen AL, Agudo A *et al.* (2012) Olive oil intake and mortality

681   within the Spanish population (EPIC-Spain). *Am J Clin Nutr* **96**, 142-149.

682   54. Martinez-Gonzalez MA, Dominguez LJ & Delgado-Rodriguez M. (2014) Olive oil

683   consumption and risk of CHD and/or stroke: a meta-analysis of case-control, cohort

684   and intervention studies. *Br J Nutr* **112**, 248-259.

685   55. Buckland G, Travier N, Barricarte A *et al.* (2012) Olive oil intake and CHD in the

686   European Prospective Investigation into Cancer and Nutrition Spanish cohort. *Br J*

687   *Nutr* **108**, 2075-2082.

688   56. Estruch R, Ros E, Salas-Salvado J *et al.* (2013) Primary prevention of

689   cardiovascular disease with a Mediterranean diet. *N Engl J Med* **368**, 1279-1290.

690   57. Guasch-Ferre M, Hu FB, Martinez-Gonzalez MA *et al.* (2014) Olive oil intake and

691   risk of cardiovascular disease and mortality in the PREDIMED Study. *BMC Med* **12**,

692   78-89.

693   58. Covas MI, Nyyssonen K, Poulsen HE *et al.* (2006) The effect of polyphenols in

694   olive oil on heart disease risk factors: a randomized trial. *Ann Intern Med* **145**, 333-

695   341.

696   59. EFSA. (2011) Scientific Opinion on the substantiation of health claims related to

697   polyphenols in olive and protection of LDL particles from oxidative damage (ID 1333,

698   1638, 1639, 1696, 2865), maintenance of normal blood HDL cholesterol

699   concentrations (ID 1639), maintenance of normal blood pressure (ID 3781), "anti-

700   inflammatory properties" (ID 1882), "contributes to the upper respiratory tract health"

701   (ID 3468), "can help to maintain a normal function of gastrointestinal tract" (3779),

702   and "contributes to body defences against external agents" (ID 3467) pursuant to

703   Article 13(1) of Regulation (EC) No 1924/2006. *EFSA Journal* **9**, 2033- 2057.

704   60. Urpi-Sarda M, Casas R, Chiva-Blanch G *et al.* (2012) Virgin olive oil and nuts as

705   key foods of the Mediterranean diet effects on inflammatory biomakers related to

706   atherosclerosis. *Pharmacol Res* **65**, 577-583.

707 61. Lou-Bonafonte JM, Arnal C, Navarro MA *et al.* (2012) Efficacy of bioactive

708 compounds from extra virgin olive oil to modulate atherosclerosis development. *Mol*

709 *Nutr Food Res* **56**, 1043-1057.

710 62. Lucas L, Russell A & Keast R. (2011) Molecular mechanisms of inflammation.

711 Anti-inflammatory benefits of virgin olive oil and the phenolic compound oleocanthal.

712 *Curr Pharm Des* **17**, 754-768.

713 63. Carluccio MA, Siculella L, Ancora MA *et al.* (2003) Olive oil and red wine

714 antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of

715 Mediterranean diet phytochemicals. *Arterioscler Thromb Vasc Biol* **23**, 622-629.

716 64. Delgado-Lista J, Garcia-Rios A, Perez-Martinez P *et al.* (2011) Olive oil and

717 haemostasis: platelet function, thrombogenesis and fibrinolysis. *Curr Pharm Des* **17**,

718 778-785.

719 65. Gillingham LG, Harris-Janz S & Jones PJ. (2011) Dietary monounsaturated fatty

720 acids are protective against metabolic syndrome and cardiovascular disease risk

721 factors. *Lipids* **46**, 209-228.

722 66. Teres S, Barcelo-Coblijn G, Benet M *et al.* (2008) Oleic acid content is responsible

723 for the reduction in blood pressure induced by olive oil. *Proceedings of the National*

724 *Academy of Sciences of the United States of America* **105**, 13811-13816.

725 67. Casaburi I, Puoci F, Chimento A *et al.* (2013) Potential of olive oil phenols as

726 chemopreventive and therapeutic agents against cancer: a review of in vitro studies.

727 *Mol Nutr Food Res* **57**, 71-83.

728 68. Pelucchi C, Bosetti C, Negri E *et al.* (2011) Olive oil and cancer risk: an update of

729 epidemiological findings through 2010. *Curr. Pharm. Des.* **17**, 805–812.

730 69. Bessaoud F, Daures JP & Gerber M. (2008) Dietary factors and breast cancer risk:

731 a case control study among a population in Southern France. *Nutr Cancer* **60**, 177-187.

732 70. Cottet V, Touvier M, Fournier A *et al.* (2009) Postmenopausal breast cancer risk

733 and dietary patterns in the E3N-EPIC prospective cohort study. *Am J Epidemiol* **170**,

734 1257-1267.

735 71. Siari S, Scali J, Richard A *et al.* (2002) Subregional variations of dietary

736 consumption and incidences of cancers in southern France. *IARC Scientific*

737 *Publications* **156**, 127-129.

738 72. Buckland G, Travier N, Agudo A *et al.* (2012) Olive oil intake and breast cancer

739 risk in the Mediterranean countries of the European Prospective Investigation into

740 Cancer and Nutrition study. *Int J Cancer* **131**, 2465-2469.

741 73. Elamin MH, Daghestani MH, Omer SA *et al.* (2013) Olive oil oleuropein has anti-
742 breast cancer properties with higher efficiency on ER-negative cells. *Food Chem*
743 *Toxicol.* **53**, 310-316.

744 74. Berr C, Portet F, Carriere I *et al.* (2009) Olive oil and cognition: results from the
745 three-city study. *Dement Geriatr Cogn Disord* **28**, 357-364.

746 75. Valls-Pedret C, Lamuela-Raventos RM, Medina-Remon A *et al.* (2012)
747 Polyphenol-rich foods in the Mediterranean diet are associated with better cognitive
748 function in elderly subjects at high cardiovascular risk. *J Alzheimers Dis* **29**, 773-782.

749 76. Martínez-Lapiscina EH, Clavero P, Toledo E *et al.* (2013;) Virgin olive oil
750 supplementation and long-term cognition: the PREDIMED-NAVARRA randomized,
751 trial. *J Nutr Health Aging* **17**, 544-552.

752 77. Gorelick PB. (2010) Role of inflammation in cognitive impairment: results of
753 observational epidemiological studies and clinical trials. *Annals of the New York*
754 *Academy of Sciences* **1207**, 155-162.

755 78. St-Laurent-Thibault C, Arseneault M, Longpre F *et al.* (2011) Tyrosol and
756 hydroxytyrosol, two main components of olive oil, protect N2a cells against amyloid-
757 beta-induced toxicity. Involvement of the NF-kappaB signaling. *Curr Alzheimer Res* **8**,
758 543-551.

759 79. Grossi C, Rigacci S, Ambrosini S *et al.* (2013) The polyphenol oleuropein
760 aglycone protects TgCRND8 mice against Ass plaque pathology. *PLoS One* **8**, e71702.

761 80. Abuznait AH, Qosa H, Busnena BA *et al.* (2013) Olive-oil-derived oleocanthal
762 enhances beta-amyloid clearance as a potential neuroprotective mechanism against
763 Alzheimer's disease: in vitro and in vivo studies. *ACS Chem Neurosci* **4**, 973-982.

764 81. Farr SA, Price TO, Dominguez LJ *et al.* (2012) Extra virgin olive oil improves
765 learning and memory in SAMP8 mice. *J Alzheimers Dis* **28**, 81-92.

766 82. Latreille J, Kesse-Guyot E, Malvy D *et al.* (2012) Dietary monounsaturated fatty
767 acids intake and risk of skin photoaging. *PLoS One* **7**, e44490.

768 83. Harland JI. (2009) An assessment of the economic and heart health benefits of
769 replacing saturated fat in the diet with monounsaturates in the form of rapeseed
770 (canola) oil. *Nutrition Bulletin* **34**, 174–184.

771 84. Lin L, Allemekinders H, Dansby A *et al.* (2013) Evidence of health benefits of
772 canola oil. *Nutr Rev* **71**, 370-385.

773 85. Bes-Rastrollo M, Schulze MB, Ruiz-Canela M *et al.* (2013) Financial conflicts of
774 interest and reporting bias regarding the association between sugar-sweetened

775 beverages and weight gain: a systematic review of systematic reviews. *PLoS Med* **10**,
776 e1001578; discussion e1001578.

777 86. Smith R. (2006) Conflicts of interest: how money clouds objectivity. *J R Soc Med*
778 **99**, 292-297.

779 87. Center for Food Safety and Applied Nutrition Qualified Health Claims – Qualified
780 Health Claims: Letter of Enforcement Discretion – Unsaturated Fatty Acids from
781 Canola Oil and Reduced Risk of Coronary Heart Disease (Docket No. 2006Q-0091).

782 88. Anses (2011) *Actualisation des apports nutritionnels conseillés pour les acides*
783 *gras.   Rapport   d'expertise   collective.*
784 pmb.santenpdc.org/opac_css/doc_num.php?explnum_id=11878.

785 89. Folsom AR & Demissie Z. (2004) Fish intake, marine omega-3 fatty acids, and
786 mortality in a cohort of postmenopausal women. *Am J Epidemiol* **160**, 1005-1010.

787 90. Albert CM, Oh K, Whang W *et al.* (2005) Dietary alpha-linolenic acid intake and
788 risk of sudden cardiac death and coronary heart disease. *Circulation* **112**, 3232-3238.

789 91. Hu FB, Stampfer MJ, Manson JE *et al.* (1999) Dietary intake of alpha-linolenic
790 acid and risk of fatal ischemic heart disease among women. *Am J Clin Nutr* **69**, 890-
791 897.

792 92. Ascherio A, Rimm EB, Giovannucci EL *et al.* (1996) Dietary fat and risk of
793 coronary heart disease in men: cohort follow up study in the United States. *BMJ* **313**,
794 84-90.

795 93. Mozaffarian D, Ascherio A, Hu FB *et al.* (2005) Interplay between different
796 polyunsaturated fatty acids and risk of coronary heart disease in men. *Circulation* **111**,
797 157-164.

798 94. Lemaitre RN, King IB, Mozaffarian D *et al.* (2003) n-3 Polyunsaturated fatty acids,
799 fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the
800 Cardiovascular Health Study. *Am J Clin Nutr* **77**, 319-325.

801 95. Pietinen P, Ascherio A, Korhonen P *et al.* (1997) Intake of fatty acids and risk of
802 coronary heart disease in a cohort of Finnish men. The Alpha-Tocopherol, Beta-
803 Carotene Cancer Prevention Study. *Am J Epidemiol* **145**, 876-887.

804 96. Oomen CM, Ocke MC, Feskens EJ *et al.* (2001) alpha-Linolenic acid intake is not
805 beneficially associated with 10-y risk of coronary artery disease incidence: the Zutphen
806 Elderly Study. *Am J Clin Nutr* **74**, 457-463.

807 97. Lemaitre RN, Sitlani C, Song X *et al.* (2012) Circulating and dietary alpha-

808 linolenic acid and incidence of congestive heart failure in older adults: the

809 Cardiovascular Health Study. *Am J Clin Nutr* **96**, 269-274.

810 98. Pan A, Chen M, Chowdhury R *et al.* (2012) alpha-Linolenic acid and risk of

811 cardiovascular disease: a systematic review and meta-analysis. *Am J Clin Nutr* **96**,

812 1262-1273.

813 99. Vedtofte MS, Jakobsen MU, Lauritzen L *et al.* (2014) Association between the

814 intake of alpha-linolenic acid and the risk of CHD. *Br J Nutr*. available on CJO2014.

815 doi:10.1017/S000711451400138X.

816 100. Wilk JB, Tsai MY, Hanson NQ *et al.* (2012) Plasma and dietary omega-3 fatty

817 acids, fish intake, and heart failure risk in the Physicians' Health Study. *Am J Clin Nutr*

818 **96**, 882-888.

819 101. Fretts AM, Mozaffarian D, Siscovick DS *et al.* (2013) Associations of plasma

820 phospholipid and dietary alpha linolenic acid with incident atrial fibrillation in older

821 adults: the Cardiovascular Health Study. *J Am Heart Assoc* **2**, e003814.

822 102. Baxheinrich A, Stratmann B, Lee-Barkey YH *et al.* (2012) Effects of a rapeseed

823 oil-enriched hypoenergetic diet with a high content of alpha-linolenic acid on body

824 weight and cardiovascular risk profile in patients with the metabolic syndrome. *Br J*

825 *Nutr* **108**, 682-691.

826 103. Lichtenstein AH, Ausman LM, Carrasco W *et al.* (1993) Effects of canola, corn,

827 and olive oils on fasting and postprandial plasma lipoproteins in humans as part of a

828 National Cholesterol Education Program Step 2 diet. *Arteriosclerosis and Thrombosis*

829 **13**, 1533-1542.

830 104. Pedersen A, Baumstark MW, Marckmann P *et al.* (2000) An olive oil-rich diet

831 results in higher concentrations of LDL cholesterol and a higher number of LDL

832 subfraction particles than rapeseed oil and sunflower oil diets. *J Lipid Res* **41**, 1901-

833 1911.

834 105. Nielsen NS, Pedersen A, Sandstrom B *et al.* (2002) Different effects of diets rich

835 in olive oil, rapeseed oil and sunflower-seed oil on postprandial lipid and lipoprotein

836 concentrations and on lipoprotein oxidation susceptibility. *Br J Nutr* **87**, 489-499.

837 106. Carleton AJ, Sievenpiper JL, de Souza R *et al.* (2013) Case-control and

838 prospective studies of dietary alpha-linolenic acid intake and prostate cancer risk: a

839 meta-analysis. *BMJ Open* **3**, 1-12.

840 107. Pelser C, Mondul AM, Hollenbeck AR *et al.* (2013) Dietary fat, fatty acids, and
841 risk of prostate cancer in the NIH-AARP diet and health study. *Cancer Epidemiol*
842 *Biomarkers Prev* **22**, 697-707.

843 108. Chajes V, Jenab M, Romieu I *et al.* (2011) Plasma phospholipid fatty acid
844 concentrations and risk of gastric adenocarcinomas in the European Prospective
845 Investigation into Cancer and Nutrition (EPIC-EURGAST). *Am J Clin Nutr* **94**, 1304-
846 1313.

847 109. Shields PG, Xu GX, Blot WJ *et al.* (1995) Mutagens from heated Chinese and
848 U.S. cooking oils. *J Natl Cancer Inst* **87**, 836-841.

849 110. Gladine C, Combe N, Vaysse C *et al.* (2013) Optimized rapeseed oil enriched
850 with healthy micronutrients: a relevant nutritional approach to prevent cardiovascular
851 diseases. Results of the Optim'Oils randomized intervention trial. *J Nutr Biochem* **24**,
852 544-549.

853 111. Obied HK, Allen MS, Bedgood DR *et al.* (2005) Bioactivity and analysis of
854 biophenols recovered from olive mill waste. *J Agric Food Chem* **53**, 823-837.

855 112. Dermechea S, Nadoura M, Larrocheb C *et al.* (2013) Olive mill wastes:
856 Biochemical characterizations and valorization strategies. *Process Biochemistry* **48**,
857 1532–1552.

858 113. De Leonardis A, Macciola V, Lembo G *et al.* (2007) Studies on oxidative
859 stabilisation of lard by natural antioxidants recovered from olive-oil mill wastewater.
860 *Food Chemistry* **100**, 998–1004.

861 114. Lafka T-I, Lazou A, Sinanoglou V *et al.* (2011) Phenolic and antioxidant potential
862 of olive oil mill wastes. *Food Chemistry* **125**, 92–98.

863 115. Fki I, Allouche N & Sayadi S. (2005) 3,4-dihydroxyphenyl acetic acid from olive
864 mill wastewater for the stabilization of refined oils: a potential alternative to synthetic
865 antioxidants. *Food Chemistry* **93**, 197–204.

866 116. Visioli F, Romani A, Mulinacci N *et al.* (1999) Antioxidant and other biological
867 activities of olive mill waste waters. *J Agric Food Chem* **47**, 3397-3401.

868 117. Barnes AP, Wreford A, Butterworth MH *et al.* (2010) Adaptation to increasing
869 severity of phoma stem canker on winter oilseed rape in the UK under climate change.
870 *J Agric Sci* **148**, 683-694.

871

Table 1 Compositions of Rapeseed Oil and Olive Oils

	Rapeseed oil [15, 17]	Olive oils [16]
Main fatty acids (g/100g)		
Palmitic acid (16:0)	3.6	7.5 - 20.0
Oleic acid (18:1)	61.6	55 - 83
Linoleic acid (18:2)	21.7	3.5 - 21.0
α-Linolenic acid (18:3)	9.6	0.0 - 1.0
Minor components (g/kg)		
Squalene	0.28	0.7 - 12.0
Carotenoids	0.01	0.001- 0.01
Phytosterols	6.9	1.0 - 2.3
Tocopherols	0.43 - 2.68	0.036 - 0.37
Phenolics	0.05	0.05 - 0.8

Table 2. Recent epidemiological studies on the health effects of olive oil

Study	Disease outcome	Study design	Subjects/cases Age range	Olive oil type	Exposure measurement	Statistics adjustments	Intake categorisation	Relative Risk (95% CI)	Trend
Samieri et al, 2011[51] (Three-City study, France)	Stroke	Prospective Median follow-up 5.25 years	7 625/148 ≥ 65 years (37.7% males)	Total OO	Frequency of broad categories food and preferred added fat	Cox model 1-Age, sex, education, study centre 2-Foods of the Med diet; other oils; animal fat; smoking; alcohol; PA; other stroke risk factors; BMI, TG, Total cholesterol	Moderate (dressing or cooking), intensive users (dressing and cooking) versus no users	Intensive users: 0.59 (0.37, 0.94)	0.02
Bendinelli et al, 2011[52] (EPICOR study, Italy)	Myocardial infarction	Prospective Follow-up average 7.85 years	29 689/144 Women 35-74 years	Total OO	Validated EPIC FFQ	Cox model 1-Energy 2- education, fruit, vegetables, meat , smoking; alcohol body weight and waist circumference	≥ 31.2 g/d versus ≤ 15.9 g/d	0.56 (0.31, 0.99)	0.04
Buckland et al, 2012[53] (EPIC-Spain)	Overall and CVD mortality	Prospective Follow-up 8 to 12 years	40 622/1 915 deaths/ 416 CVD Women 29-69 years	Total OO	Validated dietary history questionnaire 600 items	Cox model 1-Age, sex, study centre 2-non-nutritional factors: BMI, waist circumference smoking; alcohol; PA 3- Foods of the Med diet score	29.4 g/d /8.4MJ versus < 14.9 g/d /8.4MJ	Overall mortality: 0.74 (0.64, 0.87); CVD mortality 0.56 (0.40, 0.79)	<0.001 <0.001

Study	Outcome	Design	Sample	Exposure	Diet assessment	Model/adjustment	Comparison	Result (95% CI)	P
Buckland et al, 2012[55] (EPIC-Spain)	CHD incidence	Prospective Follow-up 8 to 12 years	40 142/587 29-69 years (38% males)	Total OO EVOO	Validated dietary history questionnaire 600 items	Cox model 1-Age, sex, study centre 2-nonnutritional factors: BMI, waist circumference smoking; alcohol; PA 3- Foods of the Med diet score, excluding olive oil and alcohol 4- Goldberg exclusions	≥28.9g versus <10g	0.78 (0.59, 1.03)	0.079
Guasch-Ferré et al, 2014[56] (PREDIMED Spain)	CVD events and mortality	Prospective Follow-up 4.8 years	7 216 subjects at risk for CVD/227 events/323 deaths; 67 ± 6 (42% males)	Total OO, non-virgin OO, EVOO	Validated dietary history questionnaire 137 items	Cox model 1-Age, sex, intervention group 2-non-nutritional factors: BMI, waist circumference smoking; alcohol; PA; markers of risk factors 3- Med diet score, excluding olive oil and alcohol	Total OO: 56.9 ± 10 versus 21.4 ± 8 g/d EVOO/ 34.6 ± 27.4 versus 9.1 ± 11 g/d Non virgin OO: 21.7 ± 25.1 versus 12.1 ± 11.7 g/d	*CV event total OO;* 0.65 (0.47, 0.91) EVOO 0.61 (0.44, 0.85) Non-virgin OO: NS *CV mortality* total OO 0.52 (0.73, 0.96) EVOO:NS OO: NS	0.01 <0.01 0.04
Buckland et al, 2012[71] Spain, Italy, Greece	Breast cancer	Prospective 9 year follow up	62 284/1 256 cases	Total OO	Validated FFQ	Cox model Age, education, reproductive factors fruit, vegetables, meat , smoking; alcohol body weight	30.1 g/d versus 11.1g/d	0.77 (0.48, 1.26)	
Berr et al, 2009[73]	Cognitive decline	Prospective Median	6 924 65 to ≥80	Total OO	Frequency of broad	Cox model 0-Age, sex, education,	No use versus intensive use	*Visual memory*: 0.83 (0.69,	0.01

(Three-City study, France)	follow-up 4 years	years (39.7% males)	categories food and preferred added fat	centre, baseline cognitive 1- health behaviours and health status; 2- smoking and dietary habits	0.99); *Verbal fluency* 0.85 (0.70, 1.03)

OO, olive oil; PA, physical activity; BMI, body mass index; TG, triglyceridaemia; Goldberg exclusion, exclusion of participants with poor concordance of energy intake to energy expenditure identified using Goldberg criteria

Table 3. Epidemiological studies on the health effects of dietary α-linolenic acid

Study	Disease outcome	Study design	Subjects/cases Age range	Exposure measurement	Statistics adjustments	Intake categorisation	Relative risk[‡] (95% CI)	Trend
Folsom et al 2004[88] (Iowa women health study, USA)	Total mortality	Prospective Follow-up 14 years	41 836/4 653 55-69 years	FFQ 127 items	1) Age and energy and 2) covariates previously reported to be associated with total and CV mortality in this cohort	1.21 versus 0.96 g ALA/day (supplementary analysis)	0.85 (not given)	0.01
Albert et al, 2005[89] (NHS, USA)	SCD and other CHD	Prospective Follow-up 18 years	76 763 women/ 206 SCD, 641 other CHD deaths 30-55 years	Validated FFQ	Alcohol, menopausal status, HRT, PA, aspirin, vitamin supplements, hypertension, hypercholesterolemia, diabetes, family history of MI and history of prior CVD, *trans* FA, ratio of PUFA to SFA and *n*-3 fatty acids	0.74 versus 0.31% TEI as ALA	SCD 0.60 (0.37–0.96); Other outcomes NS	0.02
Hu et al, 1999[90] (NHS, USA)	Fatal and non fatal IHD	Prospective	76 283 /232 fatal /597 non fatal IHD 30-55 years	FFQ 116 items	Age, BMI, smoking, hypertension, diabetes, hypercholesterolaemia, menopausal status, HRT, parental history of MI, multiple vitamin use, alcohol , aspirin, PA, SFA, LA, vitamins C and E, total energy	1.36 versus 0.31 g ALA/d	Fatal IHD 0.55 (0.32, 0.94); Non fatal IHD NS	0.01
Lemaitre et al, 2012[96] (Cardiovascular health	Fatal and non-fatal IHD	Prospective Follow–up 10 years	Dietary analyses 4 432/1 072; Biomarkers	FFQ with pictures Plasma concentrat	Age, sex, race, education, smoking status, BMI, waist circumference, alcohol consumption	3.2 versus 1.4l ALA as % total fat intake; % total plasma	Dietary and biomarker NS	

study)			2 957/686	ion		FA concentration women 1.64 versus 0.58 g ALA/d; men 1.62 versus 1.17 g ALA/d		
Vedtofte et al, 2014[98]	Incident CHD fatal and non-fatal	Pooled analysis of 11 prospective cohorts (criteria: ≥150 outcomes and validated FFQ or diet record) Follow-up 4–10 years	229 043 /4 493 CHD events and 1 751 CHD deaths	FFQ or diet record	BMI, education, smoking, PA, alcohol, total energy intake, SFA, *trans* FA, MUFA, LA, *n*-3 LC PUFA, dietary fibre, hypertension		Men: CHD event 0.85 (0.72, 1.01); CHD death 0.77 (0.58, 1.01). Women: CHD NS; CHD death NS	0.07§
Ascherio et al, 1996[91], (HPFUS)	Incidence of acute MI or coronary death	Prospective Follow-up 6 years	3 757/ 734 MI /229 deaths 40-75 years	Validated FFQ 131 items	Age, BMI, smoking, PA, alcohol, hypertension, cholesterol, family history of MI, fibre intake, energy	1.5 versus 0.8 g ALA/d; 1% energy increase/d	MI 0.80 (0.63 to 1.03) Death NS; MI 0.41 (0.21-0.80) Death NS	0.07
Mozaffarian et al, 2005[92]	CHD	Prospective HPFUS Follow-up 14 years	45 722/ 2 306 total CHD/ 218 sudden deaths/ 1521 nonfatal MI 40-75 years	Validated FFQ 131 items	Age, BMI, smoking, PA, alcohol, hypertension, cholesterol, family history of MI, diabetes, aspirin use, protein, SFA, fibre, MUFA, *trans* FA, energy, *n*-6 fatty acids, EPA+DHA,	1g ALA/ d + <100mg EPA+DHA	Non fatal MI 0.42 (0.23-0.75) Total CHD 0.53 (0.34-	

Study	Outcome	Design	Numbers	Dietary method	Adjustments	Comparison	Result
						1g ALA/d + ≥100mg EPA+DHA	0.83) Death NS NS
Lemaitre et al, 2003[93]	Fatal and non fatal IHD	Case-control nested in Prospective Cardiovascular Health Study, Follow-up 3 years	179 controls/ 54 fatal (male 58%)/125 non fatal (male 64%) ≥65 years	Plasma measurements	Age, study centre, sex, smoking, alcohol, TAG, HDL-cholesterol, hypertension, diabetes, congestive heart failure, claudication, heart rate, family history of MI, fibrinogen, PA. Analyse on combined PUFAs	1 SD increase in plasma concentration of ALA	NS NS for fatal and non fatal
Pietinen et al, 1997[94] (ATBC cohort, Finland)	CHD	Prospective Follow-up 6 years	21 930/1 399 events/633 deaths	Validated FFQ 276 items	Age, supplement, group several coronary risk factors, total energy and fibre intake	2.5 versus 0.9 g ALA/d	NS
Oomen et al, 2001[95] (Zutphen elderly cohort)	Coronary artery disease	Prospective	667/98	Cross-check, dietary history method	Age, standard coronary risk factors, and intake of trans fatty acids and other nutrients,	≥ 0.58 versus <0.45 % energy intake as ALA	NS
Wilk et al, 2012[99] (Physician's Health study)	Heart failure	Prospective, nested case-control.	19 097/1 572	Plasma measurements and validated FFQ	Age at time of blood sampling, atrial fibrillation, hypertension, BMI, alcohol, smoking,	Plasma ALA concentration 0.306 versus 0.097 total % FA. Dietary ALA versus 0.576 g/d	Plasma Q4 0.66 (0.47, 0.94); Q5 NS; Dietary NS

Fretts et al, 2013[100] (Cardiovascular Health Study, USA)	Incident atrial fibrillation	Prospective	4 337 ≥ 65 years	Plasma measurements and validated FFQ, 131 items	Age, sex (and total calorie intake for dietary analyses), race, education, smoking, history of heart failure, history of stroke, BMI, waist circumference, PA, hypertension, LA (for plasma measurements)	0.21 versus 0.10 % total FA,	Plasma NS Dietary NS	NS NS
Pelser et al, 2013[106] (NIH-AARP, USA)	Prostate cancer	Prospective Follow-up 9 years	288 268/23 281 (18 934 non-advanced/ 2 930 advanced/ 725 fatal) 50-71 years	Validated FFQ, 124 items	Age, race, family history, marital status, education, diabetes, PSA screening, total energy, alcohol, tomatoes, BMI in 3 levels (<25, 25 to <30, and 30 kg/m^2 and above), PA, smoking	% energy 0.41 versus 0.88	Non advanced NS Advanced 1.17 (1.04, 1.3)	0.01
Chajes et al, 2011[107] (EPIC)	Gastric adeno-carcinoma	Prospective Nested in the cohort	626/238 43 to 72 years	Plasma concentration	*H. pylori* infection, BMI, smoking, PA, education, socioeconomic status, energy intake	ALA ≥0.24 versus <0.13 as % of total fatty acids	3.20 (1.70, 6.06)	0.001

‡ when nested case-control study; § p for sex interaction

ALA, α-linolenic acid; HPFUS, Health Professional Follow-up study; HRT, hormone replacement therapy; IHD, ischaemic heart disease; LA, linoleic acid; LC, long chain; MI, myocardial infarction; NHS, Nurse's Health Study; NIH-AARP National Institute of Health Aged American Retired Persons; PA, physical activity; PSA, prostate specific antigen; Q, quintile; SD, standard deviation; SCD, sudden cardiac death; SFA, saturated fatty acids; TEI, total energy intake